Heron Therapeutics reports positive study results

Heron Therapeutics Inc. (Nasdaq: HRTX) reported positive results from a Phase 3 MAGIC study of SUSTOL sending the stock price soaring $6.86 to $19.21.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.